VEGFA and neoplasm: Bevacizumab, ramucirumab, and nintedanib act by blocking the vascular endothelial growth factor (VEGF) axis, limiting tumor vascularization and enhancing the efficacy of chemotherapy and immunotherapy backbones [84,90].